Erlotinib Prevention of Oral Cancer (EPOC).
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 29 Sep 2017
At a glance
- Drugs Erlotinib (Primary)
- Indications Orofacial cancer
- Focus Therapeutic Use
- Acronyms EPOC
- 25 Sep 2017 Planned primary completion date changed from 1 Nov 2018 to 1 Nov 2019.
- 02 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 22 Sep 2016 Planned primary completion date changed from 1 Nov 2017 to 1 Nov 2018.